|
1
|
Kim TD, Rea D, Schwarz M, Grille P,
Nicolini FE, Rosti G, Levato L, Giles FJ, Dombret H, Mirault T, et
al: Peripheral artery occlusive disease in chronic phase chronic
myeloid leukemia patients treated with nilotinib or imatinib.
Leukemia. 27:1316–1321. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
He XM, Zheng YQ, Liu SZ, Liu Y, He YZ and
Zhou XY: Altered plasma microRNAs as novel biomarkers for
arteriosclerosis obliterans. J Atheroscler Thromb. 23:196–206.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Suzuki J, Shimamura M, Suda H, Wakayama K,
Kumagai H, Ikeda Y, Akazawa H, Isobe M, Komuro I and Morishita R:
Current therapies and investigational drugs for peripheral arterial
disease. Hypertens Res. 39:183–191. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang J, He S, Wang X and Wang D: Effect
of trimetazidine on heart rate variability in elderly patients with
acute coronary syndrome. Pak J Med Sci. 32:75–78. 2016.PubMed/NCBI
|
|
5
|
Chang J, Im GJ, Chae SW, Lee SH, Kwon SY,
Jung HH, Chung AY, Park HC and Choi J: Protective role of
trimetazidine against neomycin-induced hair cell damage in
zebrafish. Clin Exp Otorhinolaryngol. 6:219–225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Atilgan D, Parlaktas BS, Uluocak N,
Erdemir F, Markoc F, Saylan O and Erkorkmaz U: The effects of
trimetazidine and sildenafil on bilateral cavernosal nerve injury
induced oxidative damage and cavernosal fibrosis in rats.
ScientificWorldJournal. 2014:9703632014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aksoy F, Dogan R, Ozturan O, Eren SB,
Veyseller B, Pektas A and Hüseyinbas Ö: Protective effect of
trimetazidine on amikacin-induced ototoxicity in rats. Int J
Pediatr Otorhinolaryngol. 78:663–669. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stadnik M, Handzlik-Orlik G, Sarnecki K,
Krysiak R and Okopień B: Clinical aspects of the use of
trimetazidine in the prevention and treatment of myocardial
diseases. Przegl Lek. 70:730–734. 2013.(In Polish). PubMed/NCBI
|
|
9
|
Rondina MT and Weyrich AS: Targeting
phosphodiesterases in anti-platelet therapy. Handb Exp Pharmacol.
210:225–238. 2012. View Article : Google Scholar
|
|
10
|
Kohda N, Tani T, Nakayama S, Adachi T,
Marukawa K, Ito R, Ishida K, Matsumoto Y and Kimura Y: Effect of
cilostazol, a phosphodiesterase III inhibitor, on experimental
thrombosis in the porcine carotid artery. Thromb Res. 96:261–268.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sakamoto T, Ohashi W, Tomita K, Hattori K,
Matsuda N and Hattori Y: Anti-inflammatory properties of
cilostazol: Its interruption of DNA binding activity of NF-κB from
the Toll-like receptor signaling pathways. Int Immunopharmacol.
62:120–131. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Criqui MH and Aboyans V: Epidemiology of
peripheral artery disease. Circ Res. 116:1509–1526. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mozaffarian D, Benjamin EJ, Go AS, Arnett
DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP,
Fullerton HJ, et al Writing Group Members; American Heart
Association Statistics Committee; Stroke Statistics Subcommittee, :
Executive Summary: Heart disease and stroke statistics - 2016
update: A report from the American Heart Association. Circulation.
133:447–454. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fowkes FG, Rudan D, Rudan I, Aboyans V,
Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ,
Mensah GA, et al: Comparison of global estimates of prevalence and
risk factors for peripheral artery disease in 2000 and 2010: A
systematic review and analysis. Lancet. 382:1329–1340. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lawall H, Huppert P, Espinola-Klein C and
Rümenapf G: The diagnosis and treatment of peripheral arterial
vascular disease. Dtsch Arztebl Int. 113:729–736. 2016.PubMed/NCBI
|
|
16
|
Chong PF, Garratt AM, Golledge J,
Greenhalgh RM and Davies AH: The intermittent claudication
questionnaire: A patient-assessed condition-specific health outcome
measure. J Vasc Surg. 36:764–771; discussion 863–864. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kurklinsky AK and Levy M: Effect of
ramipril on walking times and quality of life among patients with
peripheral artery disease and intermittent claudication: a
randomized controlled trial. Journal of the American Medical
Association 2013; 309: 453–460. Vasc Med. 18:234–236. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chao TH, Chen IC, Lee CH, Chen JY, Tsai
WC, Li YH, Tseng SY, Tsai LM and Tseng WK: Cilostazol enhances
mobilization of circulating endothelial progenitor cells and
improves endothelium-dependent function in patients at high risk of
cardiovascular disease. Angiology. 67:638–646. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
O'Donnell ME, Badger SA, Sharif MA, Young
IS, Lee B and Soong CV: The vascular and biochemical effects of
cilostazol in patients with peripheral arterial disease. J Vasc
Surg. 49:1226–1234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thompson PD, Zimet R, Forbes WP and Zhang
P: Meta-analysis of results from eight randomized,
placebo-controlled trials on the effect of cilostazol on patients
with intermittent claudication. Am J Cardiol. 90:1314–1319. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Asal NJ and Wojciak KA: Effect of
cilostazol in treating diabetes-associated microvascular
complications. Endocrine. 56:240–244. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Syrkin AL, Artiukhina EG, Kanorskiĭ SG and
Chuntyzheva MM: Antiischemic efficacy of trimetazidine in patients
with intermittent claudication and effort angina. Kardiologiia.
43:49–52. 2003.(In Russian). PubMed/NCBI
|
|
23
|
Roset PN: Systematic review of the
efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline
for the treatment of intermittent claudication (Br J Surg 2012; 99:
1630–1638). Br J Surg. 100:18382013. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
No authors listed, . Correction to: 2016
AHA/ACC Guideline on the Management of Patients With Lower
Extremity Peripheral Artery Disease: A Report of the American
College of Cardiology/American Heart Association Task Force on
Clinical Practice Guidelines. Circulation. 135:e791–e792.
2017.PubMed/NCBI
|
|
25
|
Pearce L, Ghosh J, Counsell A and
Serracino-Inglott F: Cilostazol and peripheral arterial disease.
Expert Opin Pharmacother. 9:2683–2690. 2008. View Article : Google Scholar : PubMed/NCBI
|
